Aug. 26 at 2:16 PM
$CBUS Cibus’s combination of regulatory approvals, near-term field trial catalysts, and strategic partnerships, coupled with demonstrated financial discipline, form a robust bullish thesis. Key upcoming value-driving events include sclerotinia canola trial results, biofragrance revenue initiation, and further trait approvals—each capable of triggering substantial rerating opportunities for CBUS shares.